TScan Starts Pivotal TSC-101 Trial

Company TScan Therapeutics Event Type Clinical Trial Milestone (First Patient Dosed, Pivotal Phase 3) Modality Donor-derived, TCR-engineered T-cell therapy Asset TSC-101 Target HA-2 minor histocompatibility antigen Disease Area Post-transplant AML and myelodysplastic syndrome (MDS) Summary TScan Therapeutics dosed the first patient in ALLOHA-2, its pivotal…